Smithfield Trust’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $226K | Hold |
503
| – | – | 0.01% | 347 |
|
|
2025
Q4 | $228K | Hold |
503
| – | – | 0.01% | 341 |
|
|
2025
Q3 | $198K | Hold |
503
| – | – | 0.01% | 346 |
|
|
2025
Q2 | $224K | Hold |
503
| – | – | 0.01% | 327 |
|
|
2025
Q1 | $243K | Sell |
503
-155
| -24% | -$72.2K | 0.01% | 305 |
|
|
2024
Q4 | $264K | Hold |
658
| – | – | 0.01% | 300 |
|
|
2024
Q3 | $307K | Hold |
658
| – | – | 0.02% | 282 |
|
|
2024
Q2 | $307K | Hold |
658
| – | – | 0.02% | 261 |
|
|
2024
Q1 | $276K | Sell |
658
-36
| -5% | -$15.2K | 0.01% | 279 |
|
|
2023
Q4 | $280K | Sell |
694
-126
| -15% | -$46.5K | 0.02% | 271 |
|
|
2023
Q3 | $286K | Hold |
820
| – | – | 0.02% | 248 |
|
|
2023
Q2 | $288K | Buy |
820
+10
| +1% | +$3.37K | 0.02% | 257 |
|
|
2023
Q1 | $258K | Buy |
810
+16
| +2% | +$4.8K | 0.02% | 264 |
|
|
2022
Q4 | $229K | Buy |
794
+15
| +2% | +$4.57K | 0.02% | 270 |
|
|
2022
Q3 | $225K | Buy |
779
+263
| +51% | +$75.7K | 0.02% | 257 |
|
|
2022
Q2 | $147K | Hold |
516
| – | – | 0.01% | 337 |
|
|
2022
Q1 | $135K | Sell |
516
-18
| -3% | -$4.27K | 0.01% | 372 |
|
|
2021
Q4 | $116K | Hold |
534
| – | – | 0.01% | 419 |
|
|
2021
Q3 | $98K | Sell |
534
-25
| -4% | -$4.88K | 0.01% | 442 |
|
|
2021
Q2 | $112K | Hold |
559
| – | – | 0.01% | 419 |
|
|
2021
Q1 | $120K | Hold |
559
| – | – | 0.01% | 406 |
|
|
2020
Q4 | $132K | Sell |
559
-406
| -42% | -$93.2K | 0.01% | 387 |
|
|
2020
Q3 | $263K | Sell |
965
-63
| -6% | -$17.4K | 0.02% | 244 |
|
|
2020
Q2 | $299K | Buy |
1,028
+518
| +102% | +$140K | 0.03% | 216 |
|
|
2020
Q1 | $122K | Buy |
510
+248
| +95% | +$56.9K | 0.01% | 306 |
|
|
2019
Q4 | $58K | Hold |
262
| – | – | 0.01% | 496 |
|
|
2019
Q3 | $45K | Sell |
262
-40
| -13% | -$7.08K | ﹤0.01% | 542 |
|
|
2019
Q2 | $55K | Hold |
302
| – | – | 0.01% | 509 |
|
|
2019
Q1 | $55K | Hold |
302
| – | – | 0.01% | 487 |
|
|
2018
Q4 | $50K | Hold |
302
| – | – | 0.01% | 472 |
|
|
2018
Q3 | $59K | Sell |
302
-34
| -10% | -$6.05K | 0.01% | 501 |
|
|
2018
Q2 | $57K | Sell |
336
-796
| -70% | -$123K | 0.01% | 514 |
|
|
2018
Q1 | $184K | Hold |
1,132
| – | – | 0.02% | 292 |
|
|
2017
Q4 | $170K | Buy |
1,132
+242
| +27% | +$35.8K | 0.02% | 322 |
|
|
2017
Q3 | $135K | Buy |
+890
| New | +$134K | 0.02% | 347 |
|
|
2013
Q3 | – | Sell |
-102
| Closed | -$8K | – | 772 |
|
|
2013
Q2 | $8K | Buy |
+102
| New | +$7.51K | ﹤0.01% | 656 |
|
Other funds holding VRTX
VCM
VPM
Smithfield Trust's VRTX Position: Q1 2026 in Review
Smithfield Trust held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 503 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #347.
Smithfield Trust first reported a position in VRTX in Q2 2013 and has held it in 36 quarters since. The position peaked at $307K in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Smithfield Trust held 503 shares of Vertex Pharmaceuticals worth $226K as of Q1 2026.
- Smithfield Trust left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
- Vertex Pharmaceuticals made up 0.01% of Smithfield Trust's portfolio in Q1 2026, its #347 holding.
- Smithfield Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
- Smithfield Trust's Vertex Pharmaceuticals position peaked at $307K in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.